Top Markets
#1 NKN NKN +163.44%
#2 Bluwhale Bluwhale +34.86%
#3 Codatta Codatta +29.93%
#4 SAFEcoin SAFEcoin +28.49%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.47%
#7 Yooldo Games Yooldo Games +16.45%
#8 Particle Network Particle Network +16.23%
#9 TronBank TronBank +13.65%
#10 Arcblock Arcblock +13.56%
Coin of the day
NKN NKN
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Clasificación en acciones #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Precio por acción
$0.15
Capitalización bursátil
$4.96M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
CA
Comercio Intellipharmaceutics International Inc. (IPCIF)

Categoría

Healthcare
Ingresos de Intellipharmaceutics International Inc. (IPCIF)
Ingresos en Aug 2023 TTM: $904.95K
Según los últimos informes financieros de Intellipharmaceutics International Inc., los ingresos actuales de la empresa (TTM) son $904.95K. En 2021, la empresa obtuvo unos ingresos de $65.73K una disminución en comparación con los ingresos del año 2020, que fueron de $1.40M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Intellipharmaceutics International Inc. desde 1999 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $904.95K 1,276.80%
2022 $65.73K 0.00%
2021 $65.73K -95.31%
2020 $1.40M 0.00%
2019 $1.40M -18.17%
2018 $1.71M -68.88%
2017 $5.50M 144.97%
2016 $2.25M -45.11%
2015 $4.09M -53.32%
2014 $8.77M 474.13%
2013 $1.53M 1,326.33%
2012 $107.09K -78.66%
2011 $501.81K -65.61%
2010 $1.46M 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 $1.00K 0.02%
2000 $999.82 -99.00%
1999 $100.06K 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 5,352,315.73%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 1,330,189.32%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 1,584,845.40%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 1,003,525.57%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 606,708.00%
NL